Rezolute Inc (RZLT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Rezolute Inc (RZLT) has a cash flow conversion efficiency ratio of -0.159x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-20.32 Million) by net assets ($128.00 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Rezolute Inc defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Rezolute Inc - Cash Flow Conversion Efficiency Trend (2012–2025)
This chart illustrates how Rezolute Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Rezolute Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Rezolute Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Moury Construct SA
BR:MOUR
|
0.210x |
|
Lightbridge Corporation
F:N7ON
|
-0.022x |
|
Kogeneracja SA
WAR:KGN
|
0.120x |
|
Artesian Resources Corporation
NASDAQ:ARTNA
|
0.041x |
|
Bear Creek Mining Corporation
V:BCM
|
0.192x |
|
Beijing Jiaoda Signal Technology
SHE:300851
|
0.015x |
|
Keding Enterprises Co Ltd
TW:6655
|
0.029x |
|
China Lilang Limited
F:5LX
|
0.070x |
Annual Cash Flow Conversion Efficiency for Rezolute Inc (2012–2025)
The table below shows the annual cash flow conversion efficiency of Rezolute Inc from 2012 to 2025. For the full company profile with market capitalisation and key ratios, see RZLT stock market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-06-30 | $162.13 Million | $-69.08 Million | -0.426x | +10.13% |
| 2024-06-30 | $121.00 Million | $-57.37 Million | -0.474x | -23.82% |
| 2023-06-30 | $116.17 Million | $-44.48 Million | -0.383x | -44.46% |
| 2022-06-30 | $149.47 Million | $-39.62 Million | -0.265x | +66.16% |
| 2021-06-30 | $26.10 Million | $-20.44 Million | -0.783x | +76.13% |
| 2020-06-30 | $7.37 Million | $-24.17 Million | -3.281x | +62.43% |
| 2019-06-30 | $1.75 Million | $-15.30 Million | -8.735x | -345.15% |
| 2018-06-30 | $-3.96 Million | $-14.11 Million | 3.563x | +328.28% |
| 2017-06-30 | $8.53 Million | $-13.31 Million | -1.561x | -30.56% |
| 2016-06-30 | $8.77 Million | $-10.49 Million | -1.196x | -52.91% |
| 2015-06-30 | $9.05 Million | $-7.08 Million | -0.782x | -58.15% |
| 2014-06-30 | $6.41 Million | $-3.17 Million | -0.494x | -226.40% |
| 2013-06-30 | $-4.16 Million | $-1.63 Million | 0.391x | +1147.91% |
| 2012-06-30 | $-1.29 Million | $-40.40K | 0.031x | -- |
About Rezolute Inc
Rezolute, Inc., a late-stage rare disease company, focused on improving outcomes for individuals with hypoglycemia caused by hyperinsulinism in the United States. Its lead clinical asset is ersodetug, an intravenously administered human monoclonal antibody that is in Phase 3 clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder, as well as for th… Read more